Review finds no support for cyproheptadine in feline airway inflammation
Bottom line
A new Knowledge Summary published September 17 in Veterinary Evidence concludes that cyproheptadine isn’t supported as a treatment for cats with eosinophilic airway inflammation. The review by Jillian Seeman, Rachael Kreisler, and Jeffrey Norris assessed four studies and found no current evidence that cyproheptadine monotherapy offers an immediate clinical benefit over no treatment for this indication. The paper rates the overall evidence base as moderate, but the conclusion is clear: cyproheptadine’s use for feline eosinophilic airway inflammation isn’t supported by the available data. (veterinaryevidence.org)
Why it matters: For veterinary professionals, this gives a firmer evidence-based answer around a drug that has sometimes lingered as a possible adjunct in feline airway disease discussions. The underlying studies cited in the review include experimental asthma work showing cyproheptadine did not significantly reduce eosinophilic airway inflammation, even though some sources note it may affect bronchoconstriction or airway hyperreactivity rather than inflammation itself. That distinction matters in practice, because controlling inflammation remains central to managing feline asthma-like disease. (veterinaryevidence.org)
What to watch: Watch for whether future studies test cyproheptadine only as an adjunct, at different dosing strategies, or in naturally occurring disease rather than experimental models. (merckvetmanual.com)
Key facts
- Topic
- Cyproheptadine for cats with eosinophilic airway inflammation
- Publication
- Veterinary Evidence Knowledge Summary
- Publication date
- September 17, 2026
- Study type
- Review of four studies
- Evidence rating
- Moderate
- Main finding
- No current evidence supports cyproheptadine monotherapy
- Comparison
- No treatment
- Clinical takeaway
- No demonstrated immediate benefit over no treatment
A newly published evidence review is narrowing the case for cyproheptadine in feline respiratory medicine. In a September 17, 2026 Knowledge Summary in Veterinary Evidence, researchers concluded there’s no current evidence supporting cyproheptadine monotherapy for cats with eosinophilic airway inflammation, despite longstanding interest in the drug’s antiserotonergic effects. (veterinaryevidence.org)
The question has persisted because serotonin has been implicated in allergen-induced bronchoconstriction in cats, making cyproheptadine a biologically plausible candidate. Earlier laboratory and experimental work suggested the drug could blunt serotonin-mediated bronchoconstriction or reduce airway hyperreactivity, which helped keep it in the conversation. But plausibility hasn’t translated into convincing clinical benefit on the inflammatory side of disease. (veterinaryevidence.org)
The new review examined four studies: one randomized, blinded, placebo-controlled crossover trial, one randomized crossover study, and two non-randomized controlled studies. The authors graded the collective evidence as moderate. Across those papers, two studies found cyproheptadine wasn’t useful in resolving signs of feline airway inflammation, one study found drug concentrations that blocked serotonin’s contractile effects still didn’t significantly affect muscarinic-stimulated contraction, and one study showed reduced serotonin-induced bronchoconstriction. The authors’ bottom line was that cyproheptadine monotherapy has no demonstrated immediate benefit over no treatment for feline eosinophilic airway inflammation. (veterinaryevidence.org)
That conclusion aligns with the best-known primary studies in this area. A 2007 American Journal of Veterinary Research study found cyproheptadine and cetirizine were not effective in decreasing airway eosinophilic inflammation or altering several measured immunologic variables in cats with experimentally induced asthma. Merck’s current veterinary manual also summarizes the evidence similarly, stating that in experimental feline asthma, cyproheptadine decreased airway hyperreactivity but did not significantly decrease eosinophilic airway inflammation. (pubmed.ncbi.nlm.nih.gov)
Industry and clinical commentary appears more convergent than divided. Recent feline airway disease reviews describe cyproheptadine as one of several drugs explored in experimental asthma models, but not one shown to work as effective monotherapy for airway inflammation. Some reference sources still mention it as a possible adjunct aimed at bronchoconstriction, while also noting drawbacks such as sedation, increased appetite, and the possibility that higher doses may be needed in some cats to reach therapeutic concentrations. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinarians, the practical message is less about ruling the drug out in every context and more about tightening expectations around what problem it may or may not solve. If the target is eosinophilic airway inflammation, this review supports prioritizing treatments with stronger anti-inflammatory evidence rather than reaching for cyproheptadine as a standalone option. It also underscores an important clinical distinction in feline airway disease: a drug may influence bronchoconstriction or hyperreactivity without meaningfully changing the inflammatory process driving disease progression and relapse. (veterinaryevidence.org)
That may be especially useful in conversations with pet parents seeking alternatives to corticosteroids or asking about off-label options they’ve encountered online or in referral settings. The review gives clinicians a current, citable answer: the evidence base is limited, drawn largely from experimental models, and doesn’t support cyproheptadine monotherapy for this indication. (veterinaryevidence.org)
What to watch: The next meaningful step would be better-designed studies in cats with naturally occurring disease, especially if investigators want to test cyproheptadine as an adjunct rather than a primary anti-inflammatory therapy, and to clarify whether any dosing or phenotype-specific niche truly exists. (veterinaryevidence.org)